Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives $30.44 Average Price Target from Analysts

Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the nineteen analysts that are currently covering the stock, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $30.44.

A number of analysts recently issued reports on the stock. Leerink Partnrs upgraded shares of Nurix Therapeutics to a "hold" rating in a research note on Monday, March 17th. Needham & Company LLC dropped their target price on shares of Nurix Therapeutics from $28.00 to $27.00 and set a "buy" rating for the company in a research report on Wednesday, April 9th. Leerink Partners assumed coverage on shares of Nurix Therapeutics in a research report on Monday, March 17th. They set a "market perform" rating and a $16.00 price target on the stock. JPMorgan Chase & Co. lowered their price objective on Nurix Therapeutics from $31.00 to $30.00 and set an "overweight" rating for the company in a report on Wednesday, January 29th. Finally, Stifel Nicolaus cut their price objective on Nurix Therapeutics from $36.00 to $35.00 and set a "buy" rating on the stock in a research note on Wednesday, April 9th.

Insiders Place Their Bets

In other Nurix Therapeutics news, CFO Houte Hans Van sold 2,811 shares of Nurix Therapeutics stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $19.85, for a total transaction of $55,798.35. Following the sale, the chief financial officer now owns 39,549 shares of the company's stock, valued at $785,047.65. The trade was a 6.64 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Gwenn Hansen sold 3,690 shares of the firm's stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $19.85, for a total value of $73,246.50. Following the transaction, the insider now directly owns 55,937 shares in the company, valued at $1,110,349.45. This trade represents a 6.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 12,326 shares of company stock worth $213,449. Insiders own 7.40% of the company's stock.

Institutional Trading of Nurix Therapeutics

Institutional investors have recently made changes to their positions in the stock. FMR LLC raised its holdings in Nurix Therapeutics by 1,711.9% during the fourth quarter. FMR LLC now owns 10,634,231 shares of the company's stock worth $200,349,000 after purchasing an additional 10,047,329 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Nurix Therapeutics by 8.3% in the 4th quarter. Vanguard Group Inc. now owns 4,345,266 shares of the company's stock valued at $81,865,000 after acquiring an additional 333,452 shares during the last quarter. Wellington Management Group LLP boosted its position in shares of Nurix Therapeutics by 3.0% during the 4th quarter. Wellington Management Group LLP now owns 3,586,605 shares of the company's stock valued at $67,572,000 after purchasing an additional 104,500 shares in the last quarter. Soleus Capital Management L.P. grew its stake in shares of Nurix Therapeutics by 97.3% in the 4th quarter. Soleus Capital Management L.P. now owns 2,102,833 shares of the company's stock worth $39,617,000 after purchasing an additional 1,036,999 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of Nurix Therapeutics by 9.5% in the 4th quarter. Geode Capital Management LLC now owns 1,585,127 shares of the company's stock worth $29,870,000 after purchasing an additional 137,087 shares in the last quarter.

Nurix Therapeutics Price Performance

NASDAQ NRIX traded up $0.08 on Monday, reaching $11.60. The company had a trading volume of 159,802 shares, compared to its average volume of 893,467. The firm has a market capitalization of $883.96 million, a PE ratio of -4.01 and a beta of 2.23. The firm has a 50-day moving average of $12.69 and a 200-day moving average of $18.48. Nurix Therapeutics has a 1 year low of $8.18 and a 1 year high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last issued its quarterly earnings results on Tuesday, April 8th. The company reported ($0.67) EPS for the quarter, beating analysts' consensus estimates of ($0.72) by $0.05. Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%. The firm had revenue of $18.45 million during the quarter, compared to the consensus estimate of $12.78 million. During the same quarter in the prior year, the business posted ($0.76) earnings per share. As a group, sell-side analysts expect that Nurix Therapeutics will post -2.99 EPS for the current fiscal year.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.